Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TezeBarrier Study
2024-517538-16-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tezepelumab in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Change in normalized cell index in response to barrier-damaging substances. Planned start Mar 2025; status: authorised.
02
Drugs
03
Conditions
asthmachronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2024-517538-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517538-16-00.